Announcement for the first International Research Conference: "Liver Cancer" in Heidelberg, July 5-7th 2012 initiated and organizied by the SFB/TRR77.
Dear Colleagues and Researchers,
Our three day international research conference on Liver Cancer will cover all research aspects of human liver carcinogenesis, from its initiation by chronic liver disease to its progression into metastatic cancer, its functional dissection, and the identification of novel preventive, diagnostic, and therapeutic approaches. Poster sessions and workshops will provide ample opportunities for the discussion of recent research results.
The event will be sponsored by the German Research Foundation (DFG), the European Association for Cancer Research (EACR) and by the European Association for the Study of the Liver (EASL).
You can expect an exciting program with outstanding international speakers in the inspiring atmosphere of German Cancer Research Center in the charming city of Heidelberg.
We are looking forward to your participation and hope to welcome you in Heidelberg!
Scientific Committee
Prof. P. Schirmacher
Prof. M. P. Manns
Prof. R. Bartenschlager
Prof. P. Krammer
Prof. S. Kubicka
Prof. B. Schlegelberger
-PRESSEMELDUNG-NEWS TICKER-PRESSEMELDUNG-NEWS TICKER-
Das Leberkarzinom ist weltweit der fünfthäufigste bösartige Tumor und die dritthäufigste tumorbedingte Todesursache. Seine Erforschung und Behandlung wird durch die Einrichtung eines neuen überregionalen Sonderforschungsbereiches vorangetrieben, an dem die Universität Heidelberg, die Medizinische Hochschule Hannover (MHH), das Deutsche Krebsforschungszentrum (DKFZ) und das Helmholtz-Zentrum für Infektionsforschung (HZI) beteiligt sind. Die Federführung liegt bei der Medizinischen Fakultät Heidelberg.
Die Deutsche Forschungsgemeinschaft (DFG) fördert seit Januar 2010 den Transregio-Sonderforschungsbereich „Leberkrebs – von den molekularen Entstehungsmechanismen bis zur gezielten Therapie" für zunächst vier Jahre.
Hepatocellular carcinoma (HCC) is one of the most frequent and dismal malignancies with so far limited therapeutic options but also an ideal model system for tumour research and the most relevant paradigm for virus-induced and inflammation-mediated cancer. Recent progress has demonstrated the feasibility of translating basic biomedical research findings into HCC therapy. The main aim of the SFB/TRR77 is to gain a profound understanding of the molecular basis of human hepatocarcinogenesis beginning with its initiation from chronic liver disease to its progression into metastatic cancer, its functional dissection and the identification of novel preventive, diagnostic, and therapeutic approaches by concentrating on three main goals:
- to understand general and specific mechanisms of chronic liver diseases (specifically chronic viral infection and inflammation-mediated processes) that predispose to or initiate the liver cancer and may lead to new preventive strategies (Research Area A).
- to identify and functionally characterize key molecular events that promote or sustain liver cancer and thus may serve as markers for tumour relevant functions or that may unravel promising mechanisms and targets for future therapeutic intervention (Research Area B).
- to functionally dissect specific tumor-relevant mechanisms already identified in previous research, to explore modes of translation and improve tumor targeting (Research Area C).